National Expansion of Antiretroviral Treatment in Thailand, 2000-2007: Program Scale-Up and Patient Outcomes

التفاصيل البيبلوغرافية
العنوان: National Expansion of Antiretroviral Treatment in Thailand, 2000-2007: Program Scale-Up and Patient Outcomes
المؤلفون: Sombat Thanprasertsuk, Thidaporn Jirawattanapisal, Michelle S. McConnell, Umaporn Siangphoe, Philip A. Mock, Peeramon Ningsanond, Kimberley Fox, Somchai Pinyopornpanich, Sanchai Chasombat, Cheewanan Lertpiriyasuwat, Porntip Yuktanont
المصدر: JAIDS Journal of Acquired Immune Deficiency Syndromes. 50:506-512
بيانات النشر: Ovid Technologies (Wolters Kluwer Health), 2009.
سنة النشر: 2009
مصطلحات موضوعية: Adult, Male, Pediatrics, medicine.medical_specialty, Nevirapine, Adolescent, National Health Programs, Anti-HIV Agents, HIV Infections, Health Services Accessibility, Young Adult, Pharmacotherapy, Acquired immunodeficiency syndrome (AIDS), Interquartile range, Outcome Assessment, Health Care, Humans, Medicine, Pharmacology (medical), business.industry, Proportional hazards model, Thailand, medicine.disease, Confidence interval, Community hospital, Regimen, Treatment Outcome, Infectious Diseases, Immunology, Female, business, medicine.drug
الوصف: OBJECTIVE: Thailand began a national antiretroviral (ARV) treatment program in 2000 and all government and some private and university hospitals now provide treatment to eligible HIV-infected patients. We describe program scale-up and patient outcomes from 2000 to 2007. METHODS: Data from 839 hospitals in all 76 provinces of Thailand were included in this analysis. Outcomes were assessed for patients initiating ARV treatment from January 2000 to December 2005. Follow-up data through March 2007 were included; lost to follow-up was defined as >3 months late for a follow-up visit. A Cox proportional hazard model was used to assess risk factors for death; the Kaplan-Meier method was used to estimate survival probabilities. RESULTS: Outcome data are reported for 58008 patients. Among these 52.2% were male; at treatment initiation the median age was 34 years the median CD4 count was 41 cells per cubic millimeter and 50.5% had AIDS. The initial regimen was nevirapine and 2 nonnucleoside reverse transcriptase inhibitors for 92.4% of patients; median follow-up time was 1.6 years (interquartile range = 0.8-2.4 years). Lost to follow-up occurred in 8.8% of patients. Overall 1-year survival was 0.89 (95% confidence interval = 0.88 to 0.89). Death was significantly associated with male sex age >40 years baseline CD4 count
تدمد: 1525-4135
DOI: 10.1097/qai.0b013e3181967602
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2fbd994beb57240ecb04a84b77bcb89
https://doi.org/10.1097/qai.0b013e3181967602
رقم الانضمام: edsair.doi.dedup.....d2fbd994beb57240ecb04a84b77bcb89
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15254135
DOI:10.1097/qai.0b013e3181967602